Randal W. Scott - 15 May 2026 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Reporting relationship: Director
Issuer ticker: BBIO
Reported as of: 15 May 2026
Net transaction value: -$671,456
SEC form: 4
Accepted by SEC: 19 May 2026, 16:25:29 UTC
Prior SEC filing: 18 Feb 2026
Next SEC filing: 27 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Laura Woodhead, Attorney-in-Fact

Key filing fact

Randal W. Scott filed Form 4 for BridgeBio Pharma, Inc. (BBIO) on 19 May 2026.

Key facts

This page summarizes Randal W. Scott's Form 4 filing for BridgeBio Pharma, Inc. (BBIO).
6 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 19 May 2026, 16:25.

Change

Previous filing in this sequence was filed on 18 Feb 2026.
Current net transaction value: -$671,456.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001337801 Primary reporting owner

Scott Randal W.

Relationship: Director
Address: C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO
Signature: /s/ Laura Woodhead, Attorney-in-Fact
Signature date: 19 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBIO transaction

Common Stock

Options Exercise

Transaction value
Shares: +10,000
Change %: +86%
Price: $16.75^*
Shares after: 21,589
Date: 15 May 2026
Ownership: Direct
Footnotes: F1

BBIO transaction

Common Stock

Sale

Transaction value: $413,464
Shares: -6,200
Change %: -29%
Price: $66.69
Shares after: 15,389
Date: 15 May 2026
Ownership: Direct
Footnotes: F1, F2

BBIO transaction

Common Stock

Sale

Transaction value: $141,003
Shares: -2,088
Change %: -14%
Price: $67.53
Shares after: 13,301
Date: 15 May 2026
Ownership: Direct
Footnotes: F1, F3

BBIO transaction

Common Stock

Sale

Transaction value: $103,164
Shares: -1,512
Change %: -11%
Price: $68.23
Shares after: 11,789
Date: 15 May 2026
Ownership: Direct
Footnotes: F1, F4

BBIO transaction

Common Stock

Sale

Transaction value: $13,824
Shares: -200
Change %: -1.7%
Price: $69.12
Shares after: 11,589
Date: 15 May 2026
Ownership: Direct
Footnotes: F1

BBIO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 4,000
Date: 15 May 2026
Ownership: By Thinking Bench Capital LLC

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BBIO transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -10,000
Change %: -32%
Price: $0.000000^*
Shares after: 21,501
Date: 15 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $16.75
Footnotes: F1, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025.

Footnote F2

Represents the weighted average sale price of the shares sold from $66.08 to $67.07 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Footnote F3

Represents the weighted average sale price of the shares sold from $67.10 to $68.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Footnote F4

Represents the weighted average sale price of the shares sold from $68.10 to $68.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Footnote F5

One-third of the shares underlying the option will vest on June 21, 2024; thereafter, one-third of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.